Cytokinetics: Advancing Muscle Biology, Cardiovascular Medicines and Community Health Support

Introduction

Cytokinetics, Incorporated is a U.S.-based biopharmaceutical company focused on discovering, developing and commercializing medicines that directly target muscle function. Headquartered in South San Francisco, California, Cytokinetics has spent more than 25 years advancing research in muscle biology, with a particular emphasis on cardiovascular diseases involving impaired cardiac muscle performance.

The company’s mission centers on developing medicines that may improve outcomes and healthspan for people living with serious diseases characterized by compromised muscle function. Its scientific approach focuses primarily on proteins within the sarcomere, the fundamental unit responsible for muscle contraction.

Today, Cytokinetics is a commercial-stage specialty biopharmaceutical company with activities spanning:

• Cardiovascular drug discovery.
• Hypertrophic cardiomyopathy treatment.
• Heart failure research.
• Muscle biology.
• Neuromuscular disease research.
• Clinical trials.
• Pharmaceutical commercialization.
• Patient advocacy.
• Scientific education.
• Healthcare grants.
• Corporate philanthropy.
• Community support.

In addition to its pharmaceutical research and commercial activities, Cytokinetics operates several grants and giving programs that support nonprofit organizations, patient advocacy groups, scientific education and underserved communities.

Official Cytokinetics website

History and Background

Cytokinetics was founded in 1997 by four scientists recognized for pioneering research in muscle biology and molecular motor proteins:

• James Sabry, M.D., Ph.D.
• James Spudich, Ph.D.
• Ronald Vale, Ph.D.
• Lawrence S.B. Goldstein, Ph.D.

Company operations began in 1998 in South San Francisco, California.

The scientific foundation of Cytokinetics grew from the founders’ academic discoveries involving:

• Cytoskeleton biology.
• Cellular mechanics.
• Molecular motor proteins.
• Muscle contraction.
• Protein movement inside cells.

During its early years, Cytokinetics pursued potential therapies across several disease areas, including:

• Cancer.
• Cardiovascular disease.
• Infectious disease.
• Inflammatory disease.

In 2008, the company discontinued its oncology research activities and strategically refocused its research around muscle biology.

This decision became an important turning point in the company’s history.

Cytokinetics subsequently concentrated on discovering medicines capable of directly modifying proteins responsible for muscle contraction and performance.

Over more than two decades, this scientific specialization helped the company build an extensive portfolio of intellectual property, research programs and clinical-stage medicines.

Cytokinetics reports that its scientific work has contributed to:

• More than 115 scientific publications.
• More than 100 clinical trials.
• Hundreds of issued patents.

The company entered a significant new phase in December 2025, when the U.S. Food and Drug Administration approved MYQORZO, its medicine for adults with symptomatic obstructive hypertrophic cardiomyopathy.

Commercial sales began in the United States in 2026, marking Cytokinetics’ transition from a primarily research and development-focused biotechnology company into a commercial-stage biopharmaceutical business.

Mission and Purpose

Cytokinetics’ mission is centered on developing medicines that may improve the healthspan and outcomes of people living with debilitating diseases involving impaired muscle function.

Its research has focused particularly on serious conditions such as:

• Hypertrophic cardiomyopathy.
• Heart failure.
• Neuromuscular diseases.
• Muscle weakness disorders.

The company seeks to become a leading muscle-focused specialty biopharmaceutical company, providing global access to innovative medicines arising from its scientific research.

Its corporate values emphasize four major principles:

• Patients are our North Star.
• Science is in our Soul.
• We > Me.
• Make it Happen.

These values reflect the company’s emphasis on patient-centered drug development, rigorous scientific research, teamwork and operational execution.

Scientific Focus on Muscle Biology

The central scientific strategy at Cytokinetics involves understanding and modifying the mechanisms responsible for muscle contraction.

Much of its research focuses on the sarcomere.

Sarcomeres are highly organized structures inside muscle cells that generate force during contraction.

By designing medicines that interact directly with proteins inside the sarcomere, Cytokinetics seeks to alter:

• Muscle contractility.
• Muscle strength.
• Muscle power.
• Muscle performance.
• Energy utilization.

This approach has potential applications across diseases involving both cardiac and skeletal muscles.

Governance and Structure

Cytokinetics is a publicly traded U.S. corporation listed on the Nasdaq Stock Market under the symbol CYTK.

Its governance structure includes:

• Board of Directors.
• Senior management.
• Scientific Advisory Board.
• Board committees.
• Corporate compliance systems.
• Research and development leadership.
• Commercial leadership.

The company is led by Robert I. Blum, President and Chief Executive Officer.

Blum has served as President and CEO and as a member of the Board of Directors since 2007. He has been involved with Cytokinetics since the launch of company operations in 1998.

Board of Directors

The Cytokinetics Board of Directors provides oversight of corporate strategy, financial management, executive leadership, commercialization, governance and scientific development.

As of 2026, the Board includes:

• John T. Henderson, M.B., Ch.B. – Chairman
• Robert I. Blum.
• Muna Bhanji.
• Jim Daly.
• Robert A. Harrington, M.D.
• Edward M. Kaye, M.D.
• Robert Landry.
• B. Lynne Parshall, Esq.
• Wendell Wierenga, Ph.D.
• Nancy J. Wysenski.

The Board operates through specialized committees covering areas such as:

• Audit.
• Compensation.
• Risk and compliance.
• Nominating and governance.
• Science and technology.
• Corporate transactions.

This committee structure provides additional oversight of financial, scientific, regulatory and commercial risks.

Senior Management

Cytokinetics’ executive leadership combines expertise in pharmaceutical development, finance, commercialization, regulatory affairs, business development and medical research.

Key senior executives include:

• Robert I. Blum – President and Chief Executive Officer
• Andrew Callos – Executive Vice President and Chief Commercial Officer
• Isaac Ciechanover, M.D. – Executive Vice President, Corporate Development and Chief Business Officer
• Sung Lee – Executive Vice President and Chief Financial Officer
• Fady I. Malik, M.D., Ph.D. – Executive Vice President, Research and Development
• Jeff Hessekiel – Executive Vice President, Chief Legal and Administrative Officer
• Steven M. Cook – Senior Vice President, Global Supply Chain and Technical Operations
• YulyMae DiNapoli – Senior Vice President, Human Resources

The company also maintains an extensive senior leadership structure covering clinical research, medical affairs, regulatory affairs, manufacturing, marketing, market access, finance and commercial operations.

Scientific Advisory Board

Cytokinetics also maintains a Scientific Advisory Board comprising prominent scientists and medical researchers.

Members include specialists in:

• Muscle physiology.
• Cardiovascular medicine.
• Cellular biology.
• Molecular motor proteins.
• Drug discovery.
• Chemistry.
• Neuromuscular research.

Several company co-founders continue to be represented on the Scientific Advisory Board, including Lawrence Goldstein, James Sabry and James Spudich.

The Scientific Advisory Board helps provide expert perspectives relevant to the company’s research strategy.

Funding and Business Model

Unlike a charitable foundation, Cytokinetics primarily finances its operations as a commercial biopharmaceutical company.

Its historical funding sources have included:

• Public equity offerings.
• Private equity financing.
• Strategic partnerships.
• Collaboration agreements.
• License agreements.
• Debt financing.
• Royalty monetization arrangements.
• Revenue-interest agreements.
• Investment income.
• Commercial product revenue.

The company reported approximately US$1.2 billion in cash, cash equivalents and investments at the end of 2025.

For 2025, Cytokinetics reported approximately:

• US$88 million in total revenue.
• US$416 million in research and development expenses.
• US$284 million in general and administrative expenses.

The company has historically generated significant operating losses because of the substantial costs associated with drug discovery, clinical trials, regulatory approval and pharmaceutical commercialization.

Following approval of MYQORZO, Cytokinetics increasingly expects commercial product revenue to contribute to financing its operations.

Strategic Partnerships and Licensing

Strategic collaborations are an important part of the Cytokinetics business model.

Partnerships can provide:

• Upfront payments.
• Research financing.
• Development milestones.
• Commercial milestone payments.
• Royalties.
• Regional commercialization capabilities.

One important collaboration involves Bayer.

In November 2024, Cytokinetics entered into a licensing and collaboration agreement granting Bayer exclusive rights related to the development and commercialization of aficamten in Japan, subject to certain rights retained by Cytokinetics.

The agreement included an upfront payment of €50 million and potential additional milestone payments.

Cytokinetics has also entered into licensing and collaboration arrangements with other pharmaceutical partners covering selected geographic markets.

Grants and Giving

Although Cytokinetics is primarily a pharmaceutical company, it also operates a structured Grants and Giving Program.

The company supports nonprofit organizations whose work aligns with its therapeutic interests and corporate responsibility priorities.

Funding mechanisms include:

• Grants.
• Charitable donations.
• Corporate sponsorships.
• Communications grants.
• Corporate Giving Program awards.

These programs help support:

• Patient advocacy.
• Scientific education.
• Medical education.
• Disease awareness.
• Community outreach.
• Patient and caregiver support.
• Scientific meetings.
• Research forums.
• Health equity.
• Essential community services.

Cytokinetics Grants and Giving Programs

Medical and Scientific Grants

Cytokinetics provides grants for programs and activities that increase scientific or medical knowledge in areas relevant to its therapeutic interests.

Eligible activities may include:

• Medical meetings.
• Scientific symposia.
• Research forums.
• Research roundtables.
• Professional awards.
• Scholarships.
• Disease-awareness events.
• Patient education.
• Caregiver education.
• Patient-support services.

Projects are expected to have:

• Defined objectives.
• Clear start and end dates.
• An identifiable medical or scientific need.
• Potential for meaningful impact.

The company states that supported programs may be local, regional, national or international depending on the funding mechanism.

Charitable Donations

Cytokinetics also provides charitable support for initiatives designed to improve:

• Patient care.
• Patient advocacy.
• Healthcare access.
• Community support.

Charitable funding is generally provided without requiring a significant commercial benefit to Cytokinetics.

This distinction is intended to separate genuine charitable support from promotional or commercial activity.

Corporate Sponsorships

Corporate sponsorships support events and activities that help educate communities about important health topics relevant to Cytokinetics.

Sponsorship activities can include educational meetings, community programs and other initiatives that align with the company’s healthcare interests.

Unlike charitable donations, sponsorship arrangements may include certain recognition or promotional benefits.

Corporate Giving Program

The Cytokinetics Corporate Giving Program provides charitable funding to qualifying U.S. nonprofit organizations.

The program focuses on three principal areas:

• Equitable healthcare initiatives for cardiovascular disease.
• Science education.
• Essential services for vulnerable communities.

Eligible applicants generally must be qualified 501(c)(3) nonprofit organizations in the United States and must meet Cytokinetics’ program-specific requirements.

Equitable Cardiovascular Healthcare

One priority of the Corporate Giving Program involves initiatives that improve cardiovascular health outcomes for communities with limited access to information, resources or healthcare services.

Potential projects can include:

• Public health programs.
• Disease-awareness initiatives.
• Community-led health solutions.
• Healthcare information access.
• Innovative approaches to cardiovascular health equity.
• Programs improving access to basic services.

The geographic focus for this area can include U.S.-based national initiatives or appropriate community-based programs.

Local Community Support

Cytokinetics also funds nonprofit organizations working to address essential needs in communities connected to its operations.

Priority areas include:

• Food insecurity.
• Housing insecurity.
• Food assistance.
• Housing assistance.
• Affordable housing.
• Community stability.

Local community funding is particularly focused on the San Francisco Bay Area and Greater Philadelphia Region.

Science Education

Science education forms another component of the company’s corporate giving strategy.

Programs may seek to:

• Increase access to science education.
• Encourage interest in scientific careers.
• Strengthen STEM learning.
• Provide educational opportunities for underserved communities.

Supporting science education complements the company’s broader identity as a research-driven biopharmaceutical organization.

2026 Corporate Giving Program

The 2026 Corporate Giving Program accepted applications between June 8 and August 3, 2026.

Applications were reviewed by a Cytokinetics committee based on alignment with corporate giving priorities and selection criteria.

Organizations were limited to one application during the annual review cycle.

The company indicated that funding decisions would be communicated by late November 2026.

Cytokinetics Communications Grant Program

The Cytokinetics Communications Grant Program is a dedicated funding initiative for patient advocacy organizations.

The program helps organizations strengthen:

• Communications.
• Marketing.
• Patient outreach.
• Community engagement.
• Disease awareness.
• Access to patient information.

For 2027, the Communications Grant Program opened on September 14, 2026, with applications due October 2, 2026.

The 2027 program focuses on patient advocacy organizations serving people affected by:

• Hypertrophic cardiomyopathy.
• Heart failure.

The objective is to help patient organizations undertake communications projects that might otherwise be difficult to finance.

Examples of Communications Grant Impact

In February 2026, Cytokinetics announced recipients of its eighth annual Communications Grant Program.

Two grants were awarded to organizations serving the hypertrophic cardiomyopathy community.

The grants were intended to expand:

• Patient outreach.
• Awareness.
• Community engagement.
• Communications capabilities.
• Marketing activities.

Previous versions of the program have supported multiple patient advocacy organizations annually, demonstrating Cytokinetics’ continuing investment in patient-centered communications.

Major Programs and Pharmaceutical Initiatives

Cytokinetics’ principal activities remain pharmaceutical research, clinical development and commercialization.

Its pipeline includes both approved and investigational medicines targeting diseases involving impaired muscle function.

Major programs include:

• MYQORZO.
• Aficamten development programs.
• Ulacamten.
• Omecamtiv mecarbil.
• CK-089.
• Earlier-stage muscle biology research.

MYQORZO and Aficamten

MYQORZO is the commercial brand for aficamten in approved markets.

The medicine targets cardiac myosin and was developed for hypertrophic cardiomyopathy.

As of 2026, MYQORZO is approved and commercialized in:

• United States.
• European Union.
• China.

Cytokinetics began commercial sales in the United States in early 2026.

The company subsequently announced commercial availability in Germany in June 2026 as part of its European launch.

Aficamten continues to be studied in additional patient populations and clinical settings.

Hypertrophic Cardiomyopathy Research

Hypertrophic cardiomyopathy, commonly abbreviated as HCM, is a condition in which the heart muscle becomes abnormally thick.

Cytokinetics has developed multiple clinical programs examining aficamten across different forms of HCM.

Programs include:

• SEQUOIA-HCM.
• MAPLE-HCM.
• CEDAR-HCM.
• ACACIA-HCM.

These programs investigate different patient populations and treatment questions associated with obstructive and non-obstructive HCM.

Ulacamten

Ulacamten is an investigational cardiac myosin inhibitor in Cytokinetics’ clinical pipeline.

The medicine is being evaluated in heart failure with preserved ejection fraction, commonly known as HFpEF.

Its clinical development includes the AMBER-HFpEF program.

HFpEF represents a major area of unmet medical need because affected patients can experience significant limitations in physical capacity and quality of life.

Omecamtiv Mecarbil

Omecamtiv mecarbil is a cardiac myosin activator developed to improve cardiac muscle performance.

Cytokinetics has studied the medicine in patients with heart failure with reduced ejection fraction, commonly called HFrEF.

Its clinical development includes the COMET-HF Phase 3 program.

The program illustrates the company’s broader strategy of directly modifying cardiac muscle mechanics to treat heart disease.

CK-089

CK-089 is an investigational medicine targeting skeletal muscle biology.

It is being studied for potential applications in:

• Muscular dystrophy.
• Other diseases associated with impaired skeletal muscle function.

The program remains at an earlier stage of clinical development compared with the company’s cardiovascular portfolio.

Research Beyond Current Clinical Programs

Cytokinetics continues to conduct research into the biology of muscle beyond its existing clinical pipeline.

Research areas include:

• Muscle energetics.
• Muscle growth.
• Muscle metabolism.
• Sarcomere biology.
• Cardiac muscle function.
• Skeletal muscle performance.

This research could potentially generate new medicines for additional conditions involving compromised muscle function.

Patient Advocacy and Engagement

Patient communities play an important role in Cytokinetics’ approach to drug development and corporate responsibility.

The company works with patient advocacy organizations to better understand:

• Patient experiences.
• Caregiver needs.
• Barriers to diagnosis.
• Healthcare access.
• Disease awareness.
• Educational needs.

Grant programs provide another mechanism for strengthening patient advocacy organizations independently of clinical development.

Impact and Examples of Work Funded

Cytokinetics’ impact can be divided into two broad areas:

• Scientific and pharmaceutical impact.
• Community and nonprofit funding impact.

Its scientific work has contributed to more than two decades of research into muscle biology and has produced an approved medicine as well as a broader clinical development pipeline.

At the same time, its grantmaking supports organizations working directly with patients, healthcare professionals and vulnerable communities.

Scientific Impact

The company’s scientific footprint includes:

• More than 115 publications.
• More than 100 clinical trials.
• Hundreds of issued patents.
• Multiple late-stage clinical programs.
• An approved cardiovascular medicine.
• Research partnerships worldwide.

The commercial approval of MYQORZO represented an important milestone because it demonstrated the translation of Cytokinetics’ specialized muscle biology research into an approved therapy.

Impact on Patient Communities

Cytokinetics supports patient organizations addressing diseases including hypertrophic cardiomyopathy and heart failure.

Communications grants help these organizations:

• Reach more patients.
• Provide reliable educational resources.
• Increase disease awareness.
• Connect patients with support networks.
• Improve community engagement.

These activities can be particularly important for patients living with relatively complex or under-recognized cardiovascular conditions.

Impact Through Corporate Giving

The Corporate Giving Program broadens Cytokinetics’ social impact beyond pharmaceutical research.

Supported initiatives may help communities address:

• Cardiovascular health inequality.
• Food insecurity.
• Housing insecurity.
• Lack of access to science education.
• Community health information gaps.

This approach connects the company’s scientific mission with broader determinants of health and community resilience.

Research and Development Investment

Cytokinetics invests heavily in pharmaceutical research.

In 2025 alone, research and development expenses were approximately US$416 million.

This investment supports activities such as:

• Drug discovery.
• Laboratory research.
• Preclinical development.
• Clinical trials.
• Regulatory development.
• Medical research.
• Manufacturing development.

Large research investments are typical of late-stage biopharmaceutical companies because bringing a medicine from discovery through regulatory approval can require many years of testing and substantial capital.

Commercial Transition and Future Direction

The approval of MYQORZO has changed Cytokinetics from a development-stage biotechnology company into a commercial-stage specialty pharmaceutical organization.

Its future strategy increasingly involves balancing:

• Drug discovery.
• Clinical development.
• Commercial medicine sales.
• Global expansion.
• Regulatory approvals.
• Manufacturing.
• Patient access.
• Corporate partnerships.

The company continues to pursue its long-term objective of becoming a leading muscle-focused specialty biopharmaceutical company.

Who Can Apply for Cytokinetics Grants?

Eligibility depends on the funding program.

Potential applicants may include:

• U.S. 501(c)(3) nonprofit organizations.
• Patient advocacy organizations.
• Scientific organizations.
• Medical societies.
• Community organizations.
• Educational organizations.

Programs may support activities involving:

• Cardiovascular health.
• Patient advocacy.
• Scientific education.
• Disease awareness.
• Community services.
• Health equity.
• Communications and outreach.

Applicants should carefully review the latest program guidelines because eligibility, therapeutic focus, application periods and funding priorities may change each year.

How to Apply for Cytokinetics Funding

Funding requests are generally submitted through the company’s online grants portal.

Applicants may be required to provide:

• Organization information.
• Nonprofit documentation.
• Program description.
• Objectives.
• Budget.
• Timeline.
• Intended beneficiaries.
• Expected outcomes.
• Alignment with Cytokinetics’ funding priorities.

Corporate Giving applications are reviewed by a committee of Cytokinetics representatives.

Funding of a previous project does not automatically guarantee future support.

The company also does not generally provide retroactive funding for activities that have already taken place.

Why Cytokinetics Matters

Cytokinetics occupies a distinctive position within the biotechnology industry because of its long-term specialization in muscle biology and sarcomere-directed medicines.

Its work combines:

• Basic biological research.
• Drug discovery.
• Clinical development.
• Pharmaceutical commercialization.
• International partnerships.
• Patient advocacy.
• Community philanthropy.

The company’s progression from a research-focused biotechnology startup founded in 1997 to a commercial-stage cardiovascular biopharmaceutical company illustrates the long timelines involved in translating scientific discoveries into medicines.

Its grantmaking programs further extend its reach by supporting organizations that improve patient education, community health, cardiovascular health equity and essential services.

Conclusion

Cytokinetics, Incorporated is a specialty biopharmaceutical company focused on discovering, developing and commercializing medicines that directly modify muscle function.

Founded in 1997 by pioneers in molecular motor and muscle biology research, the company began operations in South San Francisco in 1998 and later concentrated its scientific strategy around sarcomere-directed therapies.

Its pharmaceutical portfolio now spans hypertrophic cardiomyopathy, heart failure, neuromuscular disease and broader muscle biology research.

The 2025 approval of MYQORZO marked a major milestone in the company’s evolution, enabling Cytokinetics to transition into a commercial-stage biopharmaceutical organization while continuing clinical development of aficamten, ulacamten, omecamtiv mecarbil, CK-089 and additional research programs.

Beyond pharmaceutical development, Cytokinetics operates structured grants, corporate giving, charitable donation, sponsorship and communications grant programs.

These initiatives support patient advocacy, scientific education, cardiovascular health equity, community outreach, food security, housing stability and other nonprofit activities.

For more information, visit here.